GlassScriptPhysician profile
Savinder Virk
NPI 1033735014
$850.32
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $627 · 2022: $223.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $186.30 | 2021-2022 | |
| Novo Nordisk INC | $129.38 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $88.85 | 2021 | |
| Glaxosmithkline, LLC. | $64.08 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $49.87 | 2021-2022 | |
| Scilex Pharmaceuticals INC. | $44.97 | 2022 | |
| Neurocrine Biosciences, INC. | $38.49 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.38 | 2021 | |
| Novartis Pharmaceuticals Corporation | $32.90 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $27.70 | 2022 | |
| Lilly USA, LLC | $27.29 | 2021 | |
| Alkermes, INC. | $26.88 | 2022 | |
| Acerus Pharmaceuticals Corporation | $25.98 | 2021 | |
| Amarin Pharma, INC. | $22.92 | 2021 | |
| Nestle Healthcare Nutrition INC. | $16.29 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $15.35 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.61 | 2021 | |
| Intra-Sana Laboratories | $8.08 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Savinder Virk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.